CONNECTA THERAPEUTICS SL
Last verified 2026-05-08. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $2.6Mattributed |
|---|---|
| Latest round | grant, $2.6M, 2025-02-17attributed |
| Founded | 2019 |
| Headquarters | Barcelona, Spain |
| Industry | biotechnology |
| Stage | unknown |
| Website | connectatx.com |
Connecta Therapeutics is a clinical-stage biotech developing treatments for central-nervous-system disorders that lack therapies. It targets patients with neurodevelopmental and neurodegenerative diseases. Its differentiator is a first-in-class molecule, CTH120, in trials for Fragile X syndrome.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-02-17 | grant | $2.6M | undisclosed |
Detected tech stack
Nginx 1.28.0, Google Cloud CDN, Google Cloud
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $2.6M | attributed | eu-grant named as publisher. No document URL on file. |
| Total raised $2.6M | attributed | eu-grant named as publisher. No document URL on file. |
| Company existence | self-reported | connectatx.com, read 2026-05-08 |
| Description | self-reported | connectatx.com, read 2026-05-08 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.